PPT-Reimbursement Landscape for the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device

Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from thirdparty sources and is subject to change without notice as a result of complex and frequently changing laws regulations rules and policies This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice Boston Scientific encourages providers to submit accurate and appropriate claims for services . David . Osumi. -. Sutherland. What is OWL?. Web Ontology Language. Can express everything in OBO and more. .. . Certified web standard. Fast reasoning software allows:. automated ontology building; error checking; queries . Origin of limbs. Crawling. Superorder Crossopterygii. Subclass Labyrinthodontia. Transition to land. (lobe fins). Function and Trends. Locomotion. Support. Functional diversification distally. Decreased number of bones. What . did they do?. 1. . According to . Strong’s . a the definition of a watchman is this; to look out or about, . spy, keep . watch, observe, . watch.. What is a watchman?. Who or what makes a person a watchman. Meta-Analysis and Implications . David R. Holmes, Jr., M.D.. Mayo Clinic, Rochester . TCT 2014. Washington, D.C.. September 2014. Presenter Disclosure Information. David R. Holmes, Jr., M.D.. “. Watchman II: PROTECT AF/PREVAIL. Vivek Y. Reddy, MD. Helmsley Trust Professor of Medicine. Director, Cardiac Arrhythmia Service. The Mount Sinai Hospital. vivek.reddy@mountsinai.org. Grant support/Consultant. : Boston Scientific, . Percutaneous. Left Atrial Appendage (LAA) Exclusion. Aaditya Vora, MD. Cardiac Electrophysiologist. Baptist heart specialists. Disclosures. None. > . 33M. people with . AF Worldwide. 1. Many patients are unprotected. Agenda. Textbook Reimbursement (TBR). Process . Frequently Asked Questions. 2. 2015-2016 Updates. The legislature replaced the term textbook with “curricular materials”. “Curricular materials” are defined in IC 20-18-2-2.7 as . A . CASE SERIES AND REVIEW OF THE LITERATURE . 1. Lily . K. . Fatula. , BS; . 1,2. William . D. Bolton, MD; . 1,2. Barry . R. Davis, MD; . 1,2. James . E. Stephenson, MD; . 1,2. Sharon . Ben-Or, MD. . A ssessment of D ual antiplatelet therapy versus R ivaroxaban I n atrial F ibrillation patients T reated with left atrial appendage closure ADRIFT investigators DOI public at www.action-coeur.org Outcomes. . From. A . Randomized. Trial . of. . Left. . Atrial. . Appendage. . Closure. Versus Direct . Acting. Oral . Anticoagulation. in . Patients. . With. . Atrial. . Fibrillation. . CARDIAC INTERVENTIONS TODAY 29 A trial septal defect (ASD) is the second most com - mon congenital cardiac anomaly. In this article, we review the physiology of ASD, as well as the indications and m Seminar Atrial septal defectsTal Geva, Jose D Martins, Rachel M WaldAtrial septal defects are the third most common type of congenital heart disease. Included in this group of pulmonary circulations. JR. GENERAL MEDICINE. Introduction. 6-10% of all cardiac . anomalies. M:F = 1:2 [ sinus . venosus. defects 1:1. ]. 1 in 1500 live . births. Most . common congenital abnormality in adult > 40yrs [30-40. Purpose . Expedite Reimbursement Process. Funds to agencies. Standardization. Knowledge of required documentation. Accountability . Contractual guidelines. Forms. Website. Caloes.ca.gov—Divisions—Response Operations—Fire .